Bilateral sensorineural hearing loss induced by regorafenib.
WHAT IS KNOWN AND OBJECTIVE
Regorafenib is a novel multi-targeted tyrosine kinase inhibitor approved for use in refractory metastatic colorectal cancer, advanced gastrointestinal stromal tumours and hepatocellular carcinoma. We report a case of bilateral sensorineural hearing loss caused by regorafenib.


CASE SUMMARY
A 48-year-old woman was diagnosed with colon cancer that had metastasized to the liver, ureter and left ovary. She was initially treated with oral regorafenib at the lowest recommended dosage of 80 mg/d for 2 weeks, at which point the dose was increased to 120 mg/d. On the second day after the regorafenib dosage increase (ie, 15 days after starting regorafenib), she suddenly developed a bilateral hearing loss. Regorafenib was discontinued immediately, and the patient was treated with a course of intravenous steroids. Five weeks later, her bilateral hearing had subjective partial improvement.


WHAT IS NEW AND CONCLUSION
This is the first report of bilateral sensorineural hearing loss induced by regorafenib.
['Cheng|Jun|J|https://orcid.org/0000-0001-7796-1342', 'Wang|Long|L|', 'Zhu|Ling Na|LN|', 'Wang|Li|L|']
D015179:Colorectal Neoplasms D005260:Female D006312:Hearing Loss, Bilateral D006801:Humans D008875:Middle Aged D010671:Phenylurea Compounds D047428:Protein Kinase Inhibitors D011725:Pyridines
hearing loss regorafenib side effect